A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

NCT07421167 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

164

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immune Thrombocytopenia (ITP)
Primary Evans Syndrome (ES)

Interventions

BIOLOGICAL: ianalumab
DRUG: thrombopoietin receptor agonist (TPO-RA)

Sponsor

Novartis Pharmaceuticals